Added to YB: 2026-07-02
Pitch date: 2026-06-30
ABVX [neutral]
ABIVAX Société Anonyme
-1.76%
current return
Author Info
Lux Opes Research covers European companies. Lots of them. Sign up for the newsletter.
Company Info
ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases.
Market Cap
EUR 9.2B
Pitch Price
EUR 119.60
Price Target
N/A
Dividend
N/A
EV/EBITDA
-34.59
P/E
-25.53
EV/Sales
1.8K
Sector
Biotechnology
Category
special_situation
Abivax (ABVX France): Expanding safety data strengthens confidence ahead of the regulatory review
ABVX (update): New Phase III obefazimod maintenance data for hard-to-treat UC bolsters NDA package ahead of Q4 2026 filing. 45.5% regained clinical remission post dose-escalation to 50mg. Key safety reassurance: 1,700+ patient-yrs, cancer rates within UC reference ranges, no new signals easing earlier malignancy panic. Phase IIb Crohn's data mid-2027 catalyst; M&A chatter expected to flare.
Read full article (2 min)